<p>根据最近向美国证券交易委员会（SEC）披露的信息，Federated Hermes Inc. 在第四季度将其在 Entrada Therapeutics, Inc.（NASDAQ:TRDA - 免费报告）中的股份增加了 3,104.3%。该机构投资者在此期间购买了额外的 96,699 股后，持有该公司 99,814 股股票。到最近的报告期末，Federated Hermes Inc. 持有的 Entrada Therapeutics 股份约占 0.27%，价值 1,726,000 美元。</p>
<p>获取 <strong>Entrada Therapeutics</strong> 警报：</p>
<ul>
<li>Vertex Pharmaceuticals 在强劲的第一季度财报中创下历史新高</li>
</ul>
<p>其他几家大型投资者最近也增加或减少了在 TRDA 的股份。Vanguard Group Inc. 在第四季度将其在 Entrada Therapeutics 的股份增加了 19.7%。Vanguard Group Inc. 现在持有 1,464,237 股该公司的股票，价值 25,317,000 美元，在上个季度又购买了 241,052 股。Geode Capital Management LLC 在第三季度将其在 Entrada Therapeutics 的持仓增加了 8.8%。Geode Capital Management LLC 现在持有 576,451 股该公司的股票，价值 9,214,000 美元，在上个季度又收购了 46,512 股。State Street Corp 在第三季度将其在 Entrada Therapeutics 的持仓增加了 5.5%。State Street Corp 现在持有 469,601 股该公司的股票，价值 7,504,000 美元，在上个季度又收购了 24,385 股。Arrowstreet Capital Limited Partnership 在第四季度将其在 Entrada Therapeutics 的股份增加了 123.2%。Arrowstreet Capital Limited Partnership 现在持有 222,520 股该公司的股票，价值 3,847,000 美元，在上个季度又购买了 122,823 股。最后，Charles Schwab Investment Management Inc. 在第四季度将其在 Entrada Therapeutics 的持仓增加了 6.0%。Charles Schwab Investment Management Inc. 现在持有 197,127 股该公司的股票，价值 3,408,000 美元，在上个季度又购买了 11,143 股。机构投资者和对冲基金持有该公司 86.39% 的股份。</p>
<h2>Entrada Therapeutics 股票上涨 0.3%</h2>
<p>Entrada Therapeutics 的股票周二开盘价为 7.92 美元。Entrada Therapeutics, Inc. 的 12 个月低点为 7.10 美元，12 个月高点为 21.79 美元。该股票的 50 日移动平均价格为 10.69 美元，200 日移动平均价格为 14.81 美元。该股票的市值为 2.9775 亿美元，市盈率为 4.98，贝塔值为 0.04。</p>
<p>Entrada Therapeutics（NASDAQ:TRDA - 获取免费报告）最近一次发布财报是在 2 月 27 日，星期四。该公司报告本季度每股收益（EPS）为 0.03 美元，超出分析师一致预期的（0.66 美元）0.69 美元。该业务本季度的收入为 1225 万美元，而分析师预期为 1195 万美元。Entrada Therapeutics 的净利润率为 25.53%，股本回报率为 16.11%。卖方分析师预计 Entrada Therapeutics, Inc. 本年度将发布 1.12 美元的每股收益。</p>
<h2>华尔街分析师观点</h2>
<p>另外，HC Wainwright 在 3 月 31 日的报告中重申了对 Entrada Therapeutics 的 “买入” 评级，并给出了 20.00 美元的目标价。</p>
<p><strong>查看我们对 Entrada Therapeutics 的最新分析</strong></p>
<h2>关于 Entrada Therapeutics</h2>
<p>（免费报告）</p>
<p>Entrada Therapeutics, Inc. 是一家临床阶段的生物技术公司，开发用于治疗多种神经肌肉疾病的内吞体逃逸载体（EEV）疗法。其 EEV 平台开发了一系列基于寡核苷酸、抗体和酶的项目。其治疗候选药物包括 ENTR-601-44，目前正在进行杜氏肌营养不良症的 I 期临床试验；以及 ENTR-701，目前正在进行肌强直性营养不良症 1 型的 I/II 期临床试验。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票超过 Entrada Therapeutics</li>
<li>如何开始投资于便士股票</li>
<li>为什么 NVIDIA 股票尽管华尔街下调评级仍可能飙升</li>
<li>初学者如何阅读股票图表</li>
<li>第一季度内部人士购买的三只大型股：买入、卖出或持有</li>
<li>内部人士购买解析：投资者需要知道的事项</li>
<li>三只热新 IPO 逆势而上，挑战 2025 年市场低迷</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJEQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJEQQ"/></p>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Entrada Therapeutics 吗？</h2>
<p>在考虑 Entrada Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Entrada Therapeutics 并不在名单上。</p>
<p>虽然 Entrada Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TRDA

<p>Federated Hermes Inc. 在第四季度显著增加了对 Entrada Therapeutics, Inc. (NASDAQ:TRDA) 的持股，增幅达到 3,104.3%，目前持有 99,814 股，市值为 173 万美元。其他投资者如 Vanguard 和 Geode Capital 也提高了他们的持股。Entrada 的股票开盘价为 7.92 美元，12 个月的价格区间为 7.10 至 21.79 美元。该公司报告的每股收益 (EPS) 为 0.03 美元，超出预期，分析师预测当前年度的每股收益为 1.12 美元。HC Wainwright 维持 “买入” 评级，目标价为 20 美元</p>

<p>Federated Hermes Inc. boosted its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 3,104.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 99,814 shares of the company's stock after purchasing an additional 96,699 shares during the period. Federated Hermes Inc. owned about 0.27% of Entrada Therapeutics worth $1,726,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根据最近向美国证券交易委员会（SEC）披露的信息，Federated Hermes Inc. 在第四季度将其在 Entrada Therapeutics, Inc.（NASDAQ:TRDA - 免费报告）中的股份增加了 3,104.3%。该机构投资者在此期间购买了额外的 96,699 股后，持有该公司 99,814 股股票。到最近的报告期末，Federated Hermes Inc. 持有的 Entrada Therapeutics 股份约占 0.27%，价值 1,726,000 美元。</p>
</div><p>Get <strong>Entrada Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Entrada Therapeutics</strong> 警报：</p>
</div><ul>
<li>Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings</li>
</ul>
<div class="lb-trans"><ul>
<li>Vertex Pharmaceuticals 在强劲的第一季度财报中创下历史新高</li>
</ul>
</div><p>Several other large investors have also recently added to or reduced their stakes in TRDA. Vanguard Group Inc. grew its stake in shares of Entrada Therapeutics by 19.7% in the 4th quarter. Vanguard Group Inc. now owns 1,464,237 shares of the company's stock valued at $25,317,000 after buying an additional 241,052 shares in the last quarter. Geode Capital Management LLC grew its position in Entrada Therapeutics by 8.8% in the third quarter. Geode Capital Management LLC now owns 576,451 shares of the company's stock worth $9,214,000 after acquiring an additional 46,512 shares in the last quarter. State Street Corp grew its position in Entrada Therapeutics by 5.5% in the third quarter. State Street Corp now owns 469,601 shares of the company's stock worth $7,504,000 after acquiring an additional 24,385 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Entrada Therapeutics by 123.2% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 222,520 shares of the company's stock worth $3,847,000 after purchasing an additional 122,823 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Entrada Therapeutics by 6.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 197,127 shares of the company's stock valued at $3,408,000 after purchasing an additional 11,143 shares in the last quarter. Institutional investors and hedge funds own 86.39% of the company's stock.</p>
<div class="lb-trans"><p>其他几家大型投资者最近也增加或减少了在 TRDA 的股份。Vanguard Group Inc. 在第四季度将其在 Entrada Therapeutics 的股份增加了 19.7%。Vanguard Group Inc. 现在持有 1,464,237 股该公司的股票，价值 25,317,000 美元，在上个季度又购买了 241,052 股。Geode Capital Management LLC 在第三季度将其在 Entrada Therapeutics 的持仓增加了 8.8%。Geode Capital Management LLC 现在持有 576,451 股该公司的股票，价值 9,214,000 美元，在上个季度又收购了 46,512 股。State Street Corp 在第三季度将其在 Entrada Therapeutics 的持仓增加了 5.5%。State Street Corp 现在持有 469,601 股该公司的股票，价值 7,504,000 美元，在上个季度又收购了 24,385 股。Arrowstreet Capital Limited Partnership 在第四季度将其在 Entrada Therapeutics 的股份增加了 123.2%。Arrowstreet Capital Limited Partnership 现在持有 222,520 股该公司的股票，价值 3,847,000 美元，在上个季度又购买了 122,823 股。最后，Charles Schwab Investment Management Inc. 在第四季度将其在 Entrada Therapeutics 的持仓增加了 6.0%。Charles Schwab Investment Management Inc. 现在持有 197,127 股该公司的股票，价值 3,408,000 美元，在上个季度又购买了 11,143 股。机构投资者和对冲基金持有该公司 86.39% 的股份。</p>
</div><h2>Entrada Therapeutics Stock Up 0.3 %</h2>
<div class="lb-trans"><h2>Entrada Therapeutics 股票上涨 0.3%</h2>
</div><p>Shares of Entrada Therapeutics stock opened at $7.92 on Tuesday. Entrada Therapeutics, Inc. has a 12-month low of $7.10 and a 12-month high of $21.79. The stock has a 50 day moving average price of $10.69 and a two-hundred day moving average price of $14.81. The stock has a market capitalization of $297.75 million, a P/E ratio of 4.98 and a beta of 0.04.</p>
<div class="lb-trans"><p>Entrada Therapeutics 的股票周二开盘价为 7.92 美元。Entrada Therapeutics, Inc. 的 12 个月低点为 7.10 美元，12 个月高点为 21.79 美元。该股票的 50 日移动平均价格为 10.69 美元，200 日移动平均价格为 14.81 美元。该股票的市值为 2.9775 亿美元，市盈率为 4.98，贝塔值为 0.04。</p>
</div><p>Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.66) by $0.69. The business had revenue of $12.25 million for the quarter, compared to analyst estimates of $11.95 million. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. Sell-side analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.</p>
<div class="lb-trans"><p>Entrada Therapeutics（NASDAQ:TRDA - 获取免费报告）最近一次发布财报是在 2 月 27 日，星期四。该公司报告本季度每股收益（EPS）为 0.03 美元，超出分析师一致预期的（0.66 美元）0.69 美元。该业务本季度的收入为 1225 万美元，而分析师预期为 1195 万美元。Entrada Therapeutics 的净利润率为 25.53%，股本回报率为 16.11%。卖方分析师预计 Entrada Therapeutics, Inc. 本年度将发布 1.12 美元的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Separately, HC Wainwright reiterated a &#34;buy&#34; rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a report on Monday, March 31st.</p>
<div class="lb-trans"><p>另外，HC Wainwright 在 3 月 31 日的报告中重申了对 Entrada Therapeutics 的 “买入” 评级，并给出了 20.00 美元的目标价。</p>
</div><p><strong>View Our Latest Analysis on Entrada Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Entrada Therapeutics 的最新分析</strong></p>
</div><h2>About Entrada Therapeutics</h2>
<div class="lb-trans"><h2>关于 Entrada Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.</p>
<div class="lb-trans"><p>Entrada Therapeutics, Inc. 是一家临床阶段的生物技术公司，开发用于治疗多种神经肌肉疾病的内吞体逃逸载体（EEV）疗法。其 EEV 平台开发了一系列基于寡核苷酸、抗体和酶的项目。其治疗候选药物包括 ENTR-601-44，目前正在进行杜氏肌营养不良症的 I 期临床试验；以及 ENTR-701，目前正在进行肌强直性营养不良症 1 型的 I/II 期临床试验。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Entrada Therapeutics</li>
<li>How to start investing in penny stocks</li>
<li>Why NVIDIA Stock Could Soar Despite Wall Street Downgrades</li>
<li>How to Read Stock Charts for Beginners</li>
<li>Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold</li>
<li>Insider Buying Explained: What Investors Need to Know</li>
<li>3 Hot New IPOs Defying the 2025 Market Slump</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Entrada Therapeutics</li>
<li>如何开始投资于便士股票</li>
<li>为什么 NVIDIA 股票尽管华尔街下调评级仍可能飙升</li>
<li>初学者如何阅读股票图表</li>
<li>第一季度内部人士购买的三只大型股：买入、卖出或持有</li>
<li>内部人士购买解析：投资者需要知道的事项</li>
<li>三只热新 IPO 逆势而上，挑战 2025 年市场低迷</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJEQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TRDA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Entrada Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Entrada Therapeutics 吗？</h2>
</div><p>Before you consider Entrada Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Entrada Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entrada Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Entrada Therapeutics 并不在名单上。</p>
</div><p>While Entrada Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Entrada Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Federated Hermes Inc.增加了对 Entrada Therapeutics, Inc.（NASDAQ:TRDA）的股票持有量